Sepracor boosts DSP's top line but generics bite at home
This article was originally published in Scrip
The consolidation of fourth-quarter figures for its US acquisition Sepracor boosted Dainippon Sumitomo Pharma's (DSP) top line by ¥28.6 billion ($306 million) in the fiscal year to 31 March.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.